Angiotech Pharmaceuticals, Inc. (Angiotech), is a specialty pharmaceutical and medical device company that discovers, develops and markets technologies primarily focused on acute and surgical applications. The Company generates its revenue through the sales of medical products and components, as well as from royalties derived from sales by its partners of products utilizing certain of its own technologies. The Company operates in two segments: Pharmaceutical Technologies and Medical Products. The Pharmaceuticals Technologies segment includes royalty revenue generated from licensing its paclitaxel technology to various partners. The Medical Products segment manufactures and markets a range of single use, specialty medical devices. The Medical Products segment also manufactures finished medical devices and medical device components for third party medical device manufacturers and marketers.
Quick Financial Synopsis
BRIEF: For the six months ended 30 June 2009, Angiotech Pharmaceuticals, Inc.'s revenues increased less than 1% to $152.9M. Net income totaled $567K vs. a loss of $41.8M. Revenues reflect an increase in License fees. Net income also reflects a decrease in cost of products sold, lower License & royalty fees , decline in research & development expense, a decrease in selling, general & administrative expense and lower interest expense on long-term debt.
Company Address
Angiotech Pharmaceuticals, Inc.
1618 Station Street Vancouver BC V6A 1B6
P: +1604.2217676 F: +1604.2212330